Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Morgan Wallen announces 'Still the Problem' 2026 stadium tour, showcasing his continued commercial dominance despite past controversies.
Fed Chair Powell's comments on December rate cut uncertainty send markets into a mixed reaction, with Treasury yields rising and small caps falling.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier deal and intensifying the race for dominance in the lucrative obesity drug market.
Morgan Wallen announces 'Still the Problem' 2026 stadium tour, showcasing his continued commercial dominance despite past controversies.
Fed Chair Powell's comments on December rate cut uncertainty send markets into a mixed reaction, with Treasury yields rising and small caps falling.